Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of Lu AF82422 in Patients With Multiple System Atrophy

Next Previous
X
Search
Trial Profile

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of Lu AF82422 in Patients With Multiple System Atrophy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lu AF82422 (Primary)
  • Indications Multiple system atrophy
  • Focus Proof of concept; Therapeutic Use
  • Acronyms AMULET
  • Sponsors Lundbeck A/S

    • Most Recent Events

    • 14 Jun 2024 Planned End Date changed from 14 Feb 2025 to 14 May 2026.
    • 05 Mar 2024 Primary endpoint (Change From Baseline in the Unified Multiple System Atrophy Rating Scale (UMSARS) Part I and Part II Total Score (UMSARS TS) at the End of Treatment (EOT) DBP) has not been met as per results presented in Lundbeck A/S media release
    • 05 Mar 2024 According to a Lundbeck A/S media release, data from this trial will be presented at the International Conference on Alzheimers and Parkinsons Diseases and related neurological disorders (AD/PD 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top